Burke RE, Dauer WT, Vonsattel JP (2008) A critical evaluation of the Braak staging scheme for Parkinson’s disease. Ann Neurol 64(5):485–491PubMedCentralPubMed

Camicioli RM, Hanstock CC, Bouchard TP, Gee M, Fisher NJ, Martin WR (2007) Magnetic resonance spectroscopic evidence for presupplementary motor area neuronal dysfunction in Parkinson’s disease. Mov Disord 22(3):382–386PubMed

Charcot J-M (1872). De la paralysie agitante. In: Oeuvres Complètes (t1) Leçons sur les maladies du système nerveux. A Delahaye, Paris, pp. 155–188: [In English: Charcot J-M (1877) On Parkinson’s disease. In: Lectures on diseases of the nervous system delivered at the Salpêtrière (transl. Sigerson G). New Sydenham Society, London, pp. 129–156.]

Chartier-Harlin MC, Dachsel JC, Vilariño-Güell C, Lincoln SJ, Leprêtre F, Hulihan MM, Kachergus J, Milnerwood AJ, Tapia L, Song MS, Le Rhun E, Mutez E, Larvor L, Duflot A, Vanbesien-Mailliot C, Kreisler A, Ross OA, Nishioka K, Soto-Ortolaza AI, Cobb SA, Melrose HL, Behrouz B, Keeling BH, Bacon JA, Hentati E, Williams L, Yanagiya A, Sonenberg N, Lockhart PJ, Zubair AC, Uitti RJ, Aasly JO, Krygowska-Wajs A, Opala G, Wszolek ZK, Frigerio R, Maraganore DM, Gosal D, Lynch T, Hutchinson M, Bentivoglio AR, Valente EM, Nichols WC, Pankratz N, Foroud T, Gibson RA, Hentati F, Dickson DW, Destée A, Farrer MJ (2011) Translation initiator EIF4G1 mutations in familial Parkinson disease. Am J Hum Genet 89:398–406PubMedCentralPubMed

Choi J, Rees HD, Weintraub ST, Levey AI, Chin LS, Li L (2005) Oxidative modifications and aggregation of Cu, Zn-superoxide dismutase associated with Alzheimer and Parkinson diseases. J Biol Chem 280(12):11648–11655PubMed

da Costa AG, Gago MF, Garrett C (2011) Cerebrospinal fluid biomarkers for the early diagnosis of Parkinson’s disease. Article in Portuguese. Acta Med Port 24(Suppl 4):761–768PubMed

Danzer KM, Krebs SK, Wolff M, Birk G, Hengerer B (2009) Seeding induced by α-synuclein oligomers provides evidence for spreading of α-synuclein pathology. J Neurochem 111:192–203PubMed

Deeb J, Shah M, Muhammed N, Gunasekera R, Gannon K, Findley LJ, Hawkes CH (2010) A basic smell test is as sensitive as a dopamine transporter scan: comparison of olfaction, taste and DaTSCAN in the diagnosis of Parkinson’s disease. QJM 103:941–952PubMed

Dehay B, Martinez-Vicente M, Ramirez A, Perier C, Klein C, Vila M, Bezard E (2012) Lysosomal dysfunction in Parkinson disease: ATP13A2 gets into the groove. Autophagy 8(9):1389–1391PubMedCentralPubMed

Desplats P et al (2009) Inclusion formation and neuronal cell death through neuron-to-neuron transmission of α-synuclein. Proc Natl Acad Sci U S A 106:13010–13015PubMedCentralPubMed

Devic I, Hwang H, Edgar JS, Izutsu K, Presland R, Pan C, Goodlett DR, Wang Y, Armaly J, Tumas V, Zabetian CP, Leverenz JB, Shi M, Zhang J (2011) Salivary α-synuclein and DJ-1: potential biomarkers for Parkinson’s disease. Brain 134(Pt 7):e178PubMedCentralPubMed

Doty RL, Stern MB, Pfeiffer C, Gollomp SM, Hurtig HI (1992) Bilateral olfactory dysfunction in early stage treated and untreated idiopathic Parkinson’s disease. J Neurol Neurosurg Psychiatry 55:138–142PubMedCentralPubMed

Eggers C, Schwartz F, Pedrosa DJ, Kracht L, Timmermann L (2014) Parkinson’s disease subtypes show a specific link between dopaminergic and glucose metabolism in the striatum. PLoS One 9(5):e96629. doi:10.​1371/​journal.​pone.​0096629.​eCollection 2014 PubMedCentralPubMed

Friedrich C, Rüdiger H, Schmidt C, Herting B, Prieur S, Junghanns S, Schweitzer K, Globas C, Schöls L, Berg D, Reichmann H, Ziemssen T (2010) Baroreflex sensitivity and power spectral analysis during autonomic testing indifferent extrapyramidal syndromes. Mov Disord 25:315–324PubMed

Goldstein DS, Eldadah BA, Holmes C, Pechnik S, Moak J, Saleem A, Sharabi Y (2005) Neurocirculatory abnormalities in Parkinson disease with orthostatic hypotension: independence from levodopa treatment. Hypertension 46(6):1333–1339PubMed

Goldstein DS (2003) Dysautonomia in Parkinson’s disease: neurocardiological abnormalities. Lancet Neurol 2:669–676PubMed

Goldstein DS (2007) Cardiac denervation in patients with Parkinson disease. Cleve Clin J Med 74(Suppl 1):S91–S94PubMed

Goldstein DS, Sewell L, Holmes C (2010) Association of anosmia with autonomic failure in Parkinson disease. Neurology 74(3):245–251PubMedCentralPubMed

Gonera EG, Van’t Hof M, Berger HJ, van Weel C, Horstink MW (1997) Symptoms and duration of the prodromal phase in Parkinson’s disease. Mov Disord 12(6):871–876PubMed

Guo Y, Le WD, Jankovic J, Yang HR, Xu HB, Xie WJ, Song Z, Deng H (2011) Systematic genetic analysis of the PITX3 gene in patients with Parkinson disease. Mov Disord 26:1729–1732PubMed

Guttman M, Boileau I, Warsh J, Saint-Cyr JA, Ginovart N, McCluskey T, Houle S, Wilson A, Mundo E, Rusjan P, Meyer J, Kish SJ (2007) Brain serotonin transporter binding in non-depressed patients with Parkinson’s disease. Eur J Neurol 14(5):523–528PubMed

Hawkes CH, Shephard BC, Daniel SE (1997) Olfactory dysfunction in Parkinson’s disease. J Neurol Neurosurg Psychiatry 62:436–446PubMedCentralPubMed

Hilton D, Stephens M, Kirk L, Edwards P, Potter R, Zajicek J, Broughton E, Hagan H, Carroll C (2014) Accumulation of α-synuclein in the bowel of patients in the pre-clinical phase of Parkinson’s disease. Acta Neuropathol 127(2):235–241PubMed

Hong Z, Shi M, Chung KA, Quinn JF, Peskind ER, Galasko D, Jankovic J, Zabetian CP, Leverenz JB, Baird G, Montine TJ, Hancock AM, Hwang H, Pan C, Bradner J, Kang UJ, Jensen PH, Zhang J (2010) DJ-1 and alpha-synuclein in human cerebrospinal fluid as biomarkers of Parkinson’s disease. Brain 133(Pt 3):713–726PubMedCentralPubMed

Iijima M, Osawa M, Momose M, Kobayakawa T, Saito S, Iwata M, Uchiyama S (2010) Cardiac sympathetic degeneration correlates with olfactory function in Parkinson’s disease. Mov Disord 25(9):1143–1149PubMed

International Parkinson Disease Genomics Consortium, Nalls MA, Plagnol V, Hernandez DG, Sharma M, Sheerin UM, Saad M, Simón-Sánchez J, Schulte C, Lesage S, Sveinbjörnsdóttir S, Stefánsson K, Martinez M, Hardy J, Heutink P, Brice A, Gasser T, Singleton AB, Wood NW (2011) Imputation of sequence variants for identification of genetic risks for Parkinson’s disease: a meta-analysis of genome-wide association studies. Lancet 377:641–649PubMedCentral

Iranzo A, Lomeña F, Stockner H, Valldeoriola F, Vilaseca I, Salamero M, Molinuevo JL, Serradell M, Duch J, Pavía J, Gallego J, Seppi K, Högl B, Tolosa E, Poewe W, Santamaria J, Sleep Innsbruck Barcelona (SINBAR) Group (2010) Decreased striatal dopamine transporters uptake and substantia nigra hyperechogenicity as risk markers of synucleinopathy in patients with idiopathic rapid-eye-movement sleep behaviour disorder: a prospective study. Lancet Neurol 9:1070–1077PubMed

Janssen M (2012) Dopamine transporter (DaT) SPECT imaging. MI gateway 6(2) 2012.2. Society of Nuclear Medicine and Molecular Imaging (SNMMI), Reston

Jellinger KA (2009) A critical evaluation of current staging of alpha-synuclein pathology in Lewy body disorders. Biochim Biophys Acta 1792(7):730–740PubMed

Kim JS, Oh YS, Lee KS, Kim YI, Yang DW, Goldstein DS (2012) Association of cognitive dysfunction with neurocirculatory abnormalities in early Parkinson disease. Neurology 79:1323–1331PubMedCentralPubMed